Skip to content

Effect of intracoronary injection of Puyouke on myocardial infarction range in emergency PCI

Effect of intracoronary injection of Puyouke on myocardial infarction range in emergency PCI

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022290
Enrollment
Unknown
Registered
2019-04-03
Start date
2019-04-15
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Group 1:inject into 100ug nitroglycerin/sodium nitroprusside plus 10mg prourokinase
Group 2:inject into 100ug sodium nitroprusside

Sponsors

People's Hospital of The Inner Mongolia Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged =18 years, symptom onset within 12h; 2. comply with doctor's advice, patients with first onset 3. adjacent lead ST-segment elevation >1mm or new left bundle-branch block; 4. TIMI blood flow grades in emergency coronary angiography =2 level; 5. Patients who did not participate in other clinical studies; 6. Voluntarily participate in the clinical study and sign the informed consent to cooperate with patients in clinical follow-up.

Exclusion criteria

Exclusion criteria: 1. age >85 years; 2. Patients with cardiogenic shock or IABP implantation; 3. Previous cardiomyopathy or serious life-threatening diseases; 4. Hemorrhage history of gastrointestinal tract or urinary tract within half a year; 5. History of stroke within 1 year; 6. Liver and kidney dysfunction; 7. Patients with abnormal coagulation function; 8. Those with unstable hemodynamics; 9. Contrains to aspirin, clopidogrel, prourokinase, nitroglycerin and sodium nitroprusside

Design outcomes

Primary

MeasureTime frame
thrombolysis in myocardial infarction (TIMI);

Countries

China

Contacts

Public ContactZhiyong Wang

People's Hospital of The Inner Mongolia Autonomous Region

yinyx@brandentech.com+86 13884126661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026